Use of sildenafil (Viagra) in patients with cardiovascular disease  by Cheitlin, Melvin D. et al.
Use of Sildenafil (Viagra) in Patients With
Cardiovascular Disease
Writing Group Members
Melvin D. Cheitlin, MD, FACC, Cochair; Adolph M. Hutter, Jr, MD, MACC, Cochair;
Ralph G. Brindis, MD, MPH, FACC; Peter Ganz, MD, FACC; Sanjay Kaul, MD;
Richard O. Russell, Jr, MD, FACC; Randall M. Zusman, MD, FACC*
Technology and Practice Executive Committee
James S. Forrester, MD, FACC, Chair; Pamela S. Douglas, MD, FACC; David P. Faxon, MD, FACC;
John D. Fisher, MD, FACC; Raymond J. Gibbons, MD, FACC; Jonathan L. Halperin, MD, FACC;
Adolph M. Hutter, Jr, MD, MACC; Judith S. Hochman, MD, FACC; Sanjiv Kaul, MD, FACC*;
William S. Weintraub, MD, FACC; William L. Winters, Jr, MD, MACC; Michael J. Wolk, MD, FACC
Executive Summary
The pharmaceutical preparation sildenafil citrate (Viagra) is
being widely prescribed as a treatment for male erectile
dysfunction, a common problem that in the United States
affects between 10 and 30 million men. The introduction of
sildenafil has been a valuable contribution to the treatment of
erectile dysfunction, which is a relatively common occur-
rence in patients with cardiovascular disease. This article is
written to appropriately caution and not to unduly alarm
physicians in their use of sildenafil in patients with heart
disease.
Reported cardiovascular side effects in the normal healthy
population are typically minor and associated with vasodila-
tation (ie, headache, flushing, and small decreases in systolic
and diastolic blood pressures). However, although their inci-
dence is small, serious cardiovascular events, including sig-
nificant hypotension, can occur in certain populations at risk.
Most at risk are individuals who are concurrently taking
organic nitrates. Organic nitrate preparations are commonly
prescribed to manage the symptoms of angina pectoris. The
coadministration of nitrates and Viagra significantly in-
creases the risk of potentially life-threatening hypotension.
Therefore, Viagra should not be prescribed to patients receiv-
ing any form of nitrate therapy.
Although definitive evidence is currently lacking, it is
possible that a precipitous reduction in blood pressure with
nitrate use may occur over the initial 24 hours after a dose of
Viagra. Thus, for patients who experience an acute cardiac
ischemic event and who have taken Viagra within the past
24 h, administration of nitrates should be avoided. In the
event that nitrates are given, especially within this critical
time interval, it is essential to have the capability to support
the patient with fluid resuscitation and a-adrenergic agonists
if needed. In patients with recurring angina after Viagra use,
other nonnitrate antianginal agents, such as b-blockers,
should be considered.
Other patients in whom the use of Viagra is potentially
hazardous include those with active coronary ischemia; those
with congestive heart failure and borderline low blood vol-
ume and low blood pressure status; those with complicated,
multidrug, antihypertensive therapy regimens; and those tak-
ing medications that may affect the metabolic clearance of
Viagra. With respect to patients following complicated mul-
tidrug, antihypertensive programs, the randomized studies
included a large number of hypertensive patients. However,
most patients were controlled with 1 antihypertensive agent,
and only a small number were controlled with 3 antihyper-
tensive agents. Until adequate studies are done in these
subgroups of patients, sildenafil should be prescribed with
caution.
Viagra acts as a selective inhibitor of cyclic GMP
(cGMP)–specific phosphodiesterase type 5, resulting in
smooth muscle relaxation, vasodilatation, and enhanced pe-
nile erection. Although the cardiovascular effects of sildenafil
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reported in available randomized, controlled clinical trials
were relatively minor, heart disease patients represented only
a small fraction of studied patients and patients with heart
failure, patients with myocardial infarction or stroke within 6
months or patients with uncontrolled hypertension were not
included in these studies. Thus, there are possible problems in
the use of Viagra in these patients that have not been
adequately studied.
Given the increasing reports of deaths in which the use of
Viagra may be implicated, clinicians need to exercise caution
when advising their patients with heart disease about taking
this medication. Specific recommendations regarding silde-
nafil (Viagra) and the cardiac patient are summarized in the
following Table.
I. Preamble
The present document is an expert consensus. This type of
document is intended to inform practitioners, payers and
other interested parties of the opinion of the American
College of Cardiology (ACC) concerning evolving areas of
clinical practice and/or technologies that are widely available
or are new to the practice community. Topics chosen for
coverage by Expert Consensus Documents are so designated
because the evidence base and experience with the technol-
ogy or clinical practice are not sufficiently well developed to
be evaluated by the formal ACC/American Heart Association
(AHA) Practice Guidelines process. Thus, the reader should
view the Expert Consensus Documents as the best attempt of
the ACC to inform and guide clinical practice in areas in
which rigorous evidence is not yet available. Where feasible,
Expert Consensus Documents will include indications and
contraindications. Some topics covered by Expert Consensus
Documents will be addressed subsequently by the ACC/AHA
Practice Guideline process.
A. Sildenafil (Viagra) Use for Erectile Dysfunction
Male erectile dysfunction defined as “the inability to attain
and/or maintain penile erection sufficient for satisfactory
sexual performance (1)” is a common problem in the United
States affecting between 10 and 30 million men (2,3). Sexual
dysfunction in men after the diagnosis of coronary artery
disease or a myocardial infarction is common. Most is due to
fear that the exertion of sexual activity will precipitate
another myocardial infarction, but 10% to 15% is due to
organic causes of impotence (4). Approximately 5.5 million
men take nitrates on a regular basis for angina pectoris (5),
and another half a million will experience a heart attack
annually and are potential candidates for nitrate therapy (6).
Sildenafil is potentially contraindicated in as many as 6
million patients.
The introduction of sildenafil citrate (Viagra), a drug that
acts as a selective inhibitor of cGMP–specific phosphodies-
terase type 5 (PDE5), which results in smooth muscle
relaxation, vasodilatation, and enhanced penile erection, has
been a major advancement in the treatment of erectile
dysfunction (7). The vasodilating action of sildenafil affects
both the arteries and the veins, so the most frequent side effects
of sildenafil are headache and facial flushing (8). Sildenafil
causes small decreases in systolic and diastolic blood pressures,
but clinically significant hypotension is rare. Studies of sildenafil
and nitrates taken together show much greater drops in blood
pressure. For that reason, it is contraindicated to use sildenafil in
patients who take long-acting nitrates or who use short-acting,
nitrate-containing medications.
In the phase II/III studies completed before Food and Drug
Administration (FDA) approval, .3700 patients received
sildenafil and almost 2000 received placebo in double-blind
and open-label studies. None were taking long-acting nitrates,
although patients with coronary artery disease were not
excluded. Approximately 25% of the patients had hyperten-
sion and were taking antihypertensive medications, and 17%
were diabetic. In these studies, the incidence of serious
cardiovascular adverse effects was similar in the double-blind
sildenafil group, the double-blind placebo group, and the
open-label group. There were 28 patients who had a myocar-
dial infarction. When adjusted for patient-years of exposure,
there were no differences in myocardial infarction rate
between the sildenafil group and the placebo group, and no
deaths were attributed to treatment. The incidence of myo-
cardial infarction was 1.7/100 patient-years (95% CI, 0.8 to
2.6) in the sildenafil group and 1.4/100 patient-years (95%
CI, 0.2 to 2.6) in the placebo group (9). In the subsequent
analysis done in May 1998, sildenafil exposure had increased
to 4913 patient-years (693 double-blind sildenafil; 4220
open-label extensions), and 26 deaths had been reported, for
an incidence rate of 0.53/100 patient-years. The incidence for
placebo remained the same (ie, 2 deaths or 0.57/100 patient-
years) (5).
There have now been .3.6 million prescriptions (10)
written for sildenafil, and 4500 patients taking sildenafil have
been followed up without any change in the above conclu-
sions. A total of 69 deaths have been reported to the FDA as
of August 26, 1998, in patients who have used Viagra
(10,11). Twenty-one were due to unknown causes, 2 due to
stroke, and 46 related to probable cardiac events (10,11).
Twelve deaths involved a possible interaction between Vi-
agra and nitrates (10,11).
Patients with erectile dysfunction are mostly over age 45
and are in general more likely to have risk factors predispos-
ing them to cardiovascular disease, including myocardial
infarction and stroke. The vast majority of patients in the
clinical development program did not have known coronary
disease or congestive heart failure, nor were hypertensive
patients taking complicated, multidrug, antihypertensive
Summary Table of Clinical Recommendations
A. Use of Viagra clearly contraindicated
1. Concurrent use of nitrates (see Appendix A)
B. Cardiovascular effects of Viagra may be potentially hazardous (use
dependent on individual clinical assessment)
1. Patients with active coronary ischemia who are not taking nitrates (eg,
positive exercise test for ischemia)
2. Patients with congestive heart failure and borderline low blood
pressure and borderline low volume status
3. Patients on a complicated, multidrug, antihypertensive program
4. Patients taking drugs that can prolong the half-life of Viagra (see
Appendix B)
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medical regimens included in the program. Furthermore, 62%
of the patients taking Viagra were within the 45- to 64-year-
old age category, and only 23% were aged $65 years (Pfizer
Inc, unpublished data). Although sildenafil is not presently
indicated in women, the cautions referred to in this document
should probably apply to both men and women, pending
studies performed specifically in women.
B. Development of an ACC Expert
Consensus Document
In July 1998, responding to inquiries from both concerned
physicians and the press, ACC president Spencer King asked
the ACC Technology and Practice Executive Committee
(TPEC) to supervise the writing of a press release, summary
statement and Expert Consensus Document on sildenafil
(Viagra). This article was written to appropriately caution and
not to unduly alarm physicians in their use of sildenafil in
patients with heart disease.
Dr. King and TPEC chair Dr James Forrester selected a
group of physicians with specific expertise to prepare the
document. Drs. Melvin Cheitlin and Adolph Hutter, Jr, were
chosen as cochairs of the Writing Group, on the basis of their
status as well-recognized senior clinical cardiologists and
their experience in producing clinical practice guidelines.
Other members were selected for specific expertise: Dr
Brindis (managed care), Dr Ganz (vascular reactivity), Dr
Kaul (nitric oxide donors), and Dr Zusman (pharmacology of
antihypertensive agents). Dr King also invited the AHA to
jointly author the document. Dr Richard Russell (critical care
cardiology) was appointed to the Writing Group by AHA
president Dr Valentin Fuster. All members of the Writing
Group were asked to carefully review any potential conflicts
of interest they might have regarding their industry relation-
ships. Those writers who indicated conflicts are identified in
the byline.
The Writing Group reviewed both the limited published
data on Viagra and unpublished data provided by the manu-
facturer of Viagra, Pfizer Inc. With respect to the unpublished
data, all members of the Writing Group who had access to
these documents signed statements that they would not
distribute this information outside of the Writing Group until
such time as it became public information. Members of the
Writing Group were instructed to channel all communications
with Pfizer through ACC professional staff to eliminate the
appearance of bias.
After completion of the document, 10 external referees
reviewed the text. A copy of the draft was also provided to
Pfizer and to the FDA for comment. The comments from
external review, which were kept anonymous, were provided
to the Writing Group, which made revisions as they deemed
appropriate. The Expert Consensus Document was approved
by vote of the TPEC for presentation to the ACC Board of
Trustees, which voted to approve its publication in the
Journal of the American College of Cardiology. The AHA
Scientific Advisory Committee also reviewed and approved
this document for publication in Circulation.
II. Background
A. Physiology of Erection
Penile erection is accomplished by engorgement of cavernous
spaces within the corpora cavernosa under near-arterial pres-
sures and involves dilation of arterial inflow, relaxation of
corpora cavernosa smooth muscle, and constriction of venous
outflow (12). The blood flow to the penis is supplied by the
cavernosal arteries and their branches, the helicine arteries,
which empty directly into the cavernous spaces (12). Erection
is initiated by dilation of helicine arteries, resulting in marked
augmentation of blood inflow and transmission of arterial
pressures to the cavernosal spaces. Relaxation of smooth
muscle trabeculae surrounding cavernosal spaces facilitates
blood pooling and engorgement. Restriction of venous out-
flow is also essential to entrapment of blood in the corpora
cavernosa and is caused by compression of venules by the
expanding smooth muscle trabeculae against the thick tunica
albuginea (12).
B. Role of Nitric Oxide and cGMP
The relaxation of the penile arterial smooth muscle, the
corporal smooth muscle, and therefore erection is under the
control of the autonomic nervous system (13). The principal
neural mediator of penile smooth muscle relaxation is nitric
oxide (NO) (13,14). NO and its derivatives have received
much attention because they also account for the biological
activity of the endothelium-derived relaxation factor and of
organic and inorganic nitrate vasodilators. Three isoforms of
NO synthase (NOS) that convert L-arginine to NO have been
identified: neuronal (nNOS; type I NOS), inducible (iNOS;
type II NOS), and endothelial (eNOS; type III NOS). Termi-
nals containing nNOS densely innervate the corpus caverno-
sum and its arterial supply (13,14). NO derived from the
endothelium lining penile arteries and cavernosal sinuses also
participates in the erectile response. The arterial dilator
actions of NO and its relaxant effect on the smooth muscle of
the corpus cavernosum are mediated by the activation of
soluble guanylate cyclase and production of cGMP, which
acts as a second messenger (13,14). Accumulation of cGMP
leads to a reduction in intracellular calcium and smooth
muscle relaxation. The degradation of cGMP into its inactive
form, GMP, is catalyzed by cyclic nucleotide phosphodies-
terase enzymes (15,16). The predominant isoform of this
enzyme in the corpus cavernosum is PDE5 (12,15). Inhibitors
of the activity of this enzyme prevent the breakdown of
cGMP, resulting in enhanced penile erection.
III. Sildenafil
A. Introduction and Mechanism of Action
Sildenafil belongs to a class of compounds called PDE
inhibitors. PDEs comprise a diverse family of enzymes that
hydrolyze cyclic nucleotides (cAMP and cGMP) and there-
fore play a critical role in the modulation of second-
messenger signaling pathways (15).
Sildenafil is a potent and selective inhibitor of cGMP-
specific PDE5 (Pfizer, unpublished data), the predominant
isozyme that metabolizes cGMP in the corpus cavernosum of
the penis. cGMP is the second messenger of NO and, a
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principal mediator of smooth muscle relaxation and vasodi-
latation in the penis. By inhibiting the hydrolytic breakdown
of cGMP, sildenafil prolongs the action of cGMP. This
results in augmented smooth muscle relaxation and hence,
prolongation of the erection. Prior production of cGMP by
NO, released primarily from the nonadrenergic, noncholin-
ergic (nitroxidergic) cavernosal nerves in response to sexual
stimulation, is required for sildenafil to be effective (13,14).
Relatively high levels of PDE5 are found in the human
corpus cavernosum; in vascular, visceral and tracheal smooth
muscle; and in platelets (15). Sildenafil is a potent inhibitor of
PDE5, with favorable selectivity (.1000-fold) for human
PDE5 over human PDE2 (isozyme found predominantly in
the adrenal cortex) (15), PDE3 (found predominantly in
smooth muscles, platelets, and cardiac tissue) (15), and PDE4
(found predominantly in the brain and lung lymphocytes)
(15) and moderate selectivity (.80-fold) over PDE1 (a
cGMP-hydrolyzing isozyme found predominantly in the
brain, kidney, and smooth muscle) (15). Sildenafil is only
'10-fold as potent for PDE5 as for PDE6 (an enzyme found
in the photoreceptors of the human retina); this lower selec-
tivity is presumed to be the basis for abnormalities related to
color vision observed with higher doses or plasma levels of
sildenafil (Pfizer, unpublished data). The '4000-fold greater
selectivity for PDE5 over PDE3 is important because inhib-
itors of PDE3 (the isozyme involved in regulation of cardiac
contractility), such as milrinone, vesnarinone and enoximone,
that have been used in patients with heart failure, are
generally associated with increased incidence of cardiac
arrhythmias and other serious side effects (17).
B. Pharmacokinetics and Metabolism
Sildenafil is rapidly absorbed after oral administration, with
absolute bioavailability of '40%. Plasma concentrations
peak within 30 to 120 minutes (median, 60 minutes) of oral
dosing in the fasted state. Sildenafil is primarily metabolized
by the cytochrome P450 3A4 (major route) and 2C9 (minor
route) hepatic microsomal isoenzymes, which convert it to an
active N-desmethyl metabolite that has been shown to possess
50% of the parent drug’s potency for inhibiting PDE5.
Plasma concentrations of this metabolite are '40% of those
seen for sildenafil, so that the metabolite accounts for '20%
of the pharmacological effects of sildenafil. Sildenafil and its
active metabolite are both highly bound to plasma proteins
('96%), and their terminal half-lives are '4 hours each. The
mean steady-state volume of distribution for sildenafil is 105
L, indicating distribution into the tissues. Sildenafil is ex-
creted as metabolites predominantly in the feces ('80% of
administered oral dose) and to a lesser extent in the urine
('13% of the administered oral dose). Less than 0.001% of
the administered dose appears in the semen; this dose is very
unlikely to have any effects in the partners of patients taking
sildenafil. Plasma levels of sildenafil are increased in patients
aged .65 years (40% increase) and in patients with hepatic
impairment (eg, cirrhosis; 80% increase), severe renal impair-
ment (creatinine clearance ,30 mL/min; 100% increase), and
concomitant use of potent cytochrome P450 3A4 inhibitors
(eg, macrolide antibiotics such as erythromycin [200% in-
crease] and clarithromycin; cimetidine; and antifungal agents
such as ketoconazole and itraconazole) (18). Protease inhib-
itors such as indinavir, ritonavir, nelfinavir, and saquinavir
have not been formally studied but, being potent 3A4 inhib-
itors, are anticipated to have similar effects on sildenafil
metabolism (Pfizer, unpublished data).
C. Pharmacodynamics
The pharmacodynamic end points that have been investigated
with sildenafil reflect the distribution of PDE5 in different
tissues, ie, human corpus cavernosum (penile tumescence),
vascular smooth muscle (vasodilatation), and platelets (anti-
platelet function).
1. Effects on Penile Tumescence
The efficacy of sildenafil in enabling patients with erectile
dysfunction due to a broad spectrum of causes, including
vasculogenic (diabetes), neuroreflexogenic (spinal cord inju-
ry), and psychogenic (nonorganic), to achieve and maintain
erection sufficient for satisfactory sexual intercourse has been
demonstrated in all 21 double-blind, randomized, placebo-
controlled, multicenter studies (Pfizer, unpublished data).
2. Cardiovascular Effects
a. Effects on Cardiac Contractility
Unlike cAMP-specific PDE3 inhibitors (milrinone, vesnari-
none, and enoximone) that increase long-term mortality in
patients with heart failure (17,19), sildenafil is highly selec-
tive (.4000-fold) for human PDE5 over human PDE3 and
has not been found to elevate cAMP (Pfizer, unpublished
data). The cardiotoxic effects of PDE3 inhibitors are thought
to be related to increases in intracellular cAMP in the
myocardium (15,19,20). Furthermore, PDE5 is not present in
cardiac myocytes, and sildenafil has been shown to have no
direct inotropic effects on dog trabeculae muscle (Pfizer,
unpublished data). However, sildenafil has not been investi-
gated extensively in heart failure patients.
b. Effects on Blood Pressure and Heart Rate
Sildenafil produces a transient modest reduction in systolic (8
to 10 mm Hg) and diastolic (5 to 6 mm Hg) blood pressures,
with peak effects evident at 1 hour after the dose (coincident
with peak plasma concentrations) and returning to baseline
values by 4 hours after the dose (Pfizer, unpublished data).
No significant effects are observed on heart rate. The hypo-
tensive effects of sildenafil are neither age dependent (similar
reductions in blood pressure in patients aged ,65 years
compared with those .65 years) nor dose related (over the
range of 25 to 100 mg) and rarely result in reports of
orthostatic effects. Doses as high as 800 mg have been well
tolerated in some healthy volunteers (13).
c. Effects on Central Hemodynamics and Peripheral
Vasculature
In normal volunteers, no significant changes in cardiac index
were evident up to 12 h after the dose for oral sildenafil (100
to 200 mg) or intravenous sildenafil (20 to 80 mg) (Pfizer,
unpublished data). Significant decreases in systemic vascular
resistance index were reported at the end of intravenous
sildenafil infusion (20 to 80 mg), when plasma concentrations
were highest (Pfizer, unpublished data). Sildenafil has both
276 ACC/AHA Expert Consensus Document
arteriodilator and venodilator effects on the peripheral vas-
culature (Pfizer, unpublished data). In 8 patients with stable
angina, intravenous sildenafil reduced systemic and pulmo-
nary arterial pressures and cardiac output by 8%, 25%, and
7%, respectively, consistent with its mixed arterial (systemic
and pulmonary hypotension) and venous (drop in stroke
volume secondary to decreased preload) vasodilator effects
(14).
In conclusion, consistent with the anticipated effects re-
sulting from an increase in cGMP levels in vascular smooth
muscle, sildenafil possesses vasodilatory properties, which
result in mild, generally clinically insignificant decreases in
blood pressure when taken alone.
d. Platelet Effects
Sildenafil has no direct effects on platelet function but will
modestly potentiate the inhibitory effect of the NO donor
sodium nitroprusside on ADP-induced platelet aggregation ex
vivo, consistent with the requirement for an NO drive for
sildenafil to produce its pharmacological effects (Pfizer,
unpublished data). No effects on bleeding or prothrombin
times were seen in healthy subjects receiving sildenafil alone
or concurrently with aspirin or warfarin. In addition, no
adverse bleeding episodes have been reported with the use of
sildenafil (Pfizer, unpublished data). However, because the
effects of sildenafil have not been evaluated in patients with
bleeding disorders or in patients taking nonaspirin antiplatelet
agents (eg, ticlopidine, clopidogrel or dipyridamole), caution
should be exercised when the drug is administered in these
clinical settings.
3. Effects on Visual Function
Transient visual abnormalities (mostly color-tinged [blue-
green] vision, increased perception of light, and blurred
vision) have been reported in patients taking sildenafil,
especially at high oral doses (.100 mg) (Pfizer, unpublished
data). These visual effects appear to be related to the weaker
inhibiting action of sildenafil on PDE6, which regulates
signal transduction pathways in the retinal photoreceptors.
Sildenafil is 10-fold selective for PDE5 over PDE6 (Pfizer,
unpublished data). In patients with inherited disorders of
retinal PDE6, such as retinitis pigmentosa, sildenafil should
be administered with extreme caution (Pfizer, unpublished
data).
4. Adverse Effects
The adverse effects of sildenafil reflect its pharmacological
activity of inhibition of PDE5 in various tissues and can be
broadly classified into 4 major adverse reactions:
1. Vasodilatory effects resulting in headache (16%), flush-
ing (10%), and rhinitis (4%) (the latter presumably as a
result of hyperemia of nasal mucosa where PDE5 is
present). Dizziness (2%), hypotension (,2%), and pos-
tural hypotension (,2%) have been reported rarely and
occur at a similar rate in sildenafil- and placebo-treated
patients (Pfizer, unpublished data).
2. Gastrointestinal effects resulting in dyspepsia and burn-
ing sensation from reflux due to relaxation of lower
esophageal sphincter (7%) (Pfizer, unpublished data).
3. Visual abnormalities resulting in blue-green color-
tinged vision, increased perception of light, and blurred
vision (3%), especially at higher doses (Pfizer, unpub-
lished data).
4. Musculoskeletal effects resulting in myalgias, especially
with multiple daily doses. No treatment-related changes
in serum creatine kinase or electromyogram have been
observed, however (Pfizer, unpublished data). There is
no obvious pharmacological explanation for this effect.
IV. Drug-Drug Interactions and Concomitant
Disease States
A. Interaction With Nitrates
The vasodilator actions of nitrates are profoundly amplified
with concomitant use of sildenafil, resulting in major hemo-
dynamic compromise and potentially fatal events (Pfizer,
unpublished data). This interaction likely applies to all
nitrates and NO donors, irrespective of their predominant
hemodynamic site of action (see Appendix A for a list of
commonly used nitrates). Sildenafil may also potentiate the
hypotensive effects of an inhaled form of nitrate, such as
amyl nitrate or nitrite, also known as “poppers,” and therefore
is contraindicated. Poppers act by dilating blood vessels, and
the concurrent recreational use of poppers and sildenafil
could result in sudden and marked lowering of blood pres-
sure, which can be potentially serious or even fatal. This
interaction may be even more pronounced in patients taking
protease inhibitors concurrently (eg, indinavir [Crixivan],
ritonavir [Norvir], nelfinavir [Viracept], or saquinavir
[Invirase]).
Dietary sources of nitrites, nitrates, and L-arginine (the
substrate from which NO is synthesized) do not contribute to
the circulating levels of NO in humans and therefore are
unlikely to interact with sildenafil. The anesthetic agent
nitrous oxide does not undergo any detectable biotransforma-
tion and is eliminated unchanged from the body, mostly via
the lungs, usually within minutes of its administration.
Because it does not form NO in the human body and does not
itself activate guanylate cyclase, there is no contraindication
to its use after administration of sildenafil.
It is not known how much time must elapse from the time
at which a patient takes sildenafil before a nitrate-containing
medication might be given without the marked hypotensive
effect being produced. On the basis of the pharmacokinetic
profile of sildenafil, it can be assumed that the coadministra-
tion of a nitrate within the first 24 hours is likely to produce
an exaggerated hypotensive response and is therefore contra-
indicated unless the benefits are determined to far outweigh
the risks. After 24 h, the administration of a nitrate may be
considered, but once again, the response to initial dosages
must be monitored carefully. In patients in whom the half-life
of sildenafil may be prolonged (see below), a more extended
period of time from sildenafil administration to nitrate ad-
ministration may be required. The preferred form of nitrate
therapy in this setting would be short-acting intravenous
nitroglycerin infusion under close hemodynamic monitoring.
Similarly, all patients taking either sildenafil or nitrates
must be warned of the contraindications and the potential
consequences of taking sildenafil in the 24-hour interval after
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taking a nitrate preparation, including sublingual nitroglycer-
in. Although sublingual nitroglycerin is very short-acting, its
need in the previous 24 hours suggests that it may be needed
again after sildenafil-enhanced sexual relations. Furthermore,
the presence of even trace amounts of nitrates may have
unknown effects in combination with sildenafil. The admin-
istration of sildenafil to a patient who has taken a nitrate in the
preceding 24 hours is contraindicated.
Appendix A is a listing of nitrate preparations available in
the United States. Other preparations may be available in
other countries. A careful history of the medications taken by
a patient who has taken sildenafil is essential before treatment
of the patient for presumed myocardial ischemia or infarction
is initiated.
B. Interaction With Antiplatelet Agents
A clinical trial combining sildenafil with aspirin showed no
pharmacokinetic interaction between the 2 medications and
no additional effect of sildenafil on bleeding time. Dipyri-
damole is believed to exert antiplatelet effects by at least two
mechanisms. Its nonspecific PDE action increases platelet
cAMP, and it increases plasma adenosine by blocking its
reuptake by erythrocytes (21). Ticlopidine and clopidogrel
produce antiplatelet aggregatory activity by inhibiting ADP-
mediated platelet activation (22). No specific interaction
studies have been conducted between sildenafil and dipyri-
damole, ticlopidine, or clopidogrel.
C. Interaction With Other PDE Inhibitors
PDEs are considered to be major mediators of cross talk
between different second-messenger signaling pathways (15),
eg, cGMP is known to inhibit PDE3, which hydrolyzes
cAMP, thereby resulting in enhanced cAMP levels (15,20).
This increase in cAMP levels can potentially augment cAMP-
mediated effects in various tissues where PDE3 is localized,
ie, Ca21 current (ICa) and inotropy in cardiac myocytes (23),
vascular smooth muscle relaxation (24), and platelet inhibi-
tion (25). The risk of precipitating a cardiotoxic, hypotensive
or hemorrhagic event secondary to combining sildenafil with
specific PDE3 inhibitors (such as milrinone, vesnarinone or
enoximone) or with nonspecific PDE inhibitors (such as
theophylline, dipyridamole, papaverine, and pentoxifylline) is
currently unknown, but such effects are unlikely (17).
D. Drug-Drug Interactions Affecting Metabolic
Clearance of Sildenafil
Sildenafil is an inhibitor of the cytochrome P450 2C9
metabolic pathway. It is possible that the administration of
sildenafil could result in a significant increase in the plasma
concentrations of other drugs metabolized through this path-
way. Although tolbutamide and warfarin are metabolized by
the P450 2C9 pathway, there is no evidence to date that the
concomitant administration of sildenafil affects the metabolic
clearance of these 2 drugs.
Sildenafil is predominantly metabolized by both the P450
2C9 pathway and the P450 3A4 pathway (a low-affinity but
high-capacity system). Thus, potent inhibitors of the P450
3A4 pathway may increase the plasma concentrations of
sildenafil and therefore its pharmacological effect. Cimeti-
dine and erythromycin are commonly prescribed drugs that
inhibit the P450 3A4 pathway. As indicated in the approved
product labeling, the simultaneous administration of either of
these agents significantly increases the plasma concentrations
of sildenafil; a lower initial dose (25 mg) should be consid-
ered in the coadministration of sildenafil to patients receiving
either of these agents.
Many drugs are metabolized by the P450 3A4 pathway but
are not inhibitors of the pathway. The coadministration of 1
of these drugs may lead to a competitive inhibition of the
metabolism of sildenafil, although the 3A4 system is a
high-capacity enzymatic system. The effects of these agents
on the half-life, physiological effects, and side effects of
sildenafil are unknown; physicians should be cognizant of the
potential interaction of such agents. Appendix B includes a
partial listing of commonly prescribed drugs metabolized via
the P450 3A4 pathway.
E. Concomitant Administration of
Antihypertensive Drugs
Sildenafil administration has been associated with reductions
in blood pressure (compared with placebo) of as much as
8/5 mm Hg (systolic/diastolic values). In a drug interaction
study of sildenafil and amlodipine, the additional blood
pressure reduction in the patient population receiving both
sildenafil and amlodipine was not significantly different from
the population receiving sildenafil and a placebo (Pfizer,
unpublished data). Although formal drug-drug interaction
studies have not been conducted with the following medica-
tions, no increase in blood pressure–related adverse events or
systematic enhancement of the blood pressure–lowering ef-
fects of thiazide, loop and potassium-sparing diuretics, ACE
inhibitors, calcium channel blockers, or a- or b-adrenergic
receptor antagonists have been observed in clinical trials.
However, the potential for a hypotensive reaction in patients
taking antihypertensive medications as well as sildenafil must
be considered and the patient alerted to this possibility.
Although not supported by data from the clinical trials, there
may be a theoretical concern in a patient receiving multiple
medications that include antihypertensive therapy and an
inhibitor of the metabolic pathway (cytochrome P450 3A4) of
sildenafil.
F. Concomitant Disease States
1. Renal Dysfunction
Patients with severe renal impairment (creatinine clearance
,30 mL/min) have a reduced clearance of sildenafil. Plasma
levels of the parent drug and of its metabolites in patients with
severe renal impairment are approximately twice those found
in healthy subjects. Thus, the duration of the effect of
sildenafil in these patients will be prolonged and also may be
enhanced at any given dosage of the medication. Particular
care should be taken in the administration of concomitant
medications that may lower blood pressure in patients receiv-
ing sildenafil whose renal function is severely impaired. The
effects of less-severe degrees of renal dysfunction on the
metabolism of sildenafil have been evaluated. There were no
significant effects on the metabolism of sildenafil seen in
subjects with mild (creatinine clearance 50 to 80 mL/min) or
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moderate (creatinine clearance 30 to 49 mL/min) renal
impairment (24). Of note, the plasma creatinine concentration
of the elderly patient with a lower body mass may not
accurately reflect the patient’s creatinine clearance, and thus
initiation of therapy at 25 mg rather than 50 mg may be
appropriate in the elderly.
2. Hepatic Dysfunction
Patients with hepatic dysfunction have a decreased clearance
of sildenafil compared with normal subjects. Plasma concen-
trations of sildenafil and of its metabolites may be signifi-
cantly increased in patients with hepatic dysfunction. Under
such conditions, the duration of activity of sildenafil may be
prolonged and the extent of its effects enhanced. As in
patients with renal dysfunction, the initiation of therapy at 25
mg rather than 50 mg may be appropriate in patients with
hepatic dysfunction.
V. Cardiovascular Effects of Sexual
Intercourse in Patients With Coronary
Artery Disease
There is potential for a high incidence of overt and covert
coronary artery disease in patients with erectile dysfunction
on the basis of the epidemiological profiles of both patient
groups. Therefore, when prescribing sildenafil, physicians
should consider the potential implications of coronary artery
disease in sedentary patients who plan to resume sexual
activity. Because nitrates are contraindicated for the manage-
ment of coronary ischemic syndromes in patients taking
sildenafil, review of the patient’s ability to tolerate the
cardiovascular stresses involved with sexual intercourse,
particularly patients with coronary artery disease or at in-
creased risk of coronary artery disease, may aid the treating
physician in patient management.
Cardiac and metabolic expenditures during sexual inter-
course will vary depending on the type of sexual activity. In
a laboratory setting, healthy males with their usual female
partners achieved an average peak heart rate of 110 bpm with
woman-on-top coitus and an average peak heart rate of 127
bpm with man-on-top coitus (26). When oxygen uptake was
measured in these men, an average metabolic expenditure
during stimulation and orgasm of 2.5 metabolic equivalents
(METS) for woman-on-top coitus and 3.3 METS for man-
on-top coitus was attained. There was a significant individual
variation of cardiovascular responses among patients ranging
from 2.0 to 5.4 METS for man-on-top coitus. Thus, to simply
equate a level of cardiac or metabolic expenditure during
sexual intercourse to an activity such as “climbing 1 or 2
flights of stairs” may underestimate the level of cardiovascu-
lar response in individual patients.
In patients with known coronary artery disease whose
antianginal medicines were stopped for study purposes (27),
Drory et al compared the electrocardiographic monitoring
findings in sexual activity with a near-maximal exercise
treadmill test (ETT). Most patients had previous myocardial
infarctions and were in New York Heart Association func-
tional class I or II. ECG criteria for ischemia during inter-
course were found in one third of the patients; two thirds of
the time, this was silent rather than symptomatic ischemia.
All patients with ischemia during coitus also demonstrated
ischemia at ETT. Drory et al also noted significant variation
in heart rate response to coitus, with an average heart rate of
118 bpm but with some patients attaining a heart rate of 185
bpm at orgasm. Other small studies with ECG monitoring
during intercourse in patients with coronary artery disease
concluded that sexual activity may provoke increased ven-
tricular ectopic activity that is not necessarily elicited by
other stimuli (28). Jackson (29) found that in 19 patients with
ischemic heart disease who developed angina during sexual
intercourse, these symptoms were abolished with b-blockade.
The mean maximum heart rate during sexual intercourse with
and without use of b-blockers was 82 and 122 bpm, respec-
tively. This would suggest that these patients may have
different hemodynamics while taking antianginal medication
that may afford them some protection or lower their risk of
ischemia. It should be emphasized that coital death is rare,
encompassing only 0.6% of sudden death cases (30). Muller
et al (31) found by retrospective case-crossover methodology
that although sexual activity can trigger the onset of myocar-
dial infarction, the relative risk in the 2 hours after sexual
activity is very low (2.5; 95% CI, 1.7 to 3.7). Furthermore,
sexual activity was a likely contributor to the onset of
myocardial infarction only 0.9% of the time. Additionally,
they found that the relative risk of myocardial infarction is
not increased in patients with a prior history of cardiac
disease and that regular exercise appears to prevent trigger-
ing. It should be cautioned that these reassuring data should
not be extrapolated to patients taking sildenafil if they
perform at higher cardiac and metabolic expenditures during
coitus. The hemodynamic changes associated with sexual
activity may be far greater with an unfamiliar than with a
familiar partner, in unfamiliar settings, and after excessive
eating and consumption of alcohol. The person most at risk is
usually middle-aged and having extramarital relations.
The ETT can gauge the potential cardiac stress of sexual
activity. If a patient can achieve 5 or 6 METS on the ETT
without demonstrating arrhythmias or ischemia electrocardio-
graphically, they most likely are not at high risk for devel-
oping myocardial ischemia as a result of their normal sexual
activities.
VI. Recommendations for Sildenafil and the
Cardiac Patient
A. Prescribing Sildenafil to Patients at
Clinical Risk
1. Sildenafil is absolutely contraindicated in patients un-
dergoing any long-acting nitrate drug therapy or using
short-acting nitrates because of the risk of developing
potentially life-threatening hypotension.
2. If a patient has stable coronary disease, is not taking a
long-acting nitrate, has short-acting nitrate use as the
only contraindication to sildenafil, and does not appear
to need the nitrate on a consistent basis, the physician
and the patient should carefully weigh the risks and
benefits of sildenafil treatment. If the patient requires
nitrates for mild or moderate exercise limitation, sil-
denafil should probably not be used.
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3. All patients taking organic nitrates, even if they have
not asked for Viagra, should be informed about the
nitrate-sildenafil hypotensive interaction. There is a
substantial potential for patients to obtain Viagra from
another physician, a friend, or through the “black
market,” circumventing healthcare providers who could
offer appropriate caution. Because sildenafil also poten-
tiates the hypotensive effect of an inhaled form of
nitrate such as amyl nitrate or poppers, the concurrent
recreational use of poppers and sildenafil could result in
sudden and marked hypotensive response that could be
serious or fatal. This interaction may be more pro-
nounced in patients taking protease inhibitors concur-
rently (eg, indinavir, ritonavir, nelfinavir, and
saquinavir).
4. Similarly, patients must be warned of the contraindica-
tion of taking sildenafil in the 24-hour time interval
after taking a nitrate preparation, including sublingual
nitroglycerin. The administration of sildenafil to a
patient who has taken a nitrate in any form in the
preceding 24 hours is contraindicated.
5. Although firm data are lacking, pre-Viagra treadmill
tests to assess for the presence of stress-induced ische-
mia in patients with overt and covert coronary artery
disease can guide the patient and physician relative to
the risk of cardiac ischemia during sexual intercourse. If
the patient can achieve $5 to 6 METS on an ETT
without demonstrating ischemia, the risk of ischemia
during coitus with a familiar partner, in familiar set-
tings, without the added stress of a heavy meal or
alcohol ingestion, is probably low. We wish to stress
that the physical and emotional stresses of sexual
intercourse can be excessive in some people, particu-
larly those who have not performed this activity in some
time and who are not in good condition. These stresses
themselves may produce acute ischemia or precipitate
myocardial infarction. Such patients should be advised
to use common sense and to moderate their physical
exertion and their emotional expectations was they
begin their experience with taking Viagra.
6. If patients are taking a combination of antihypertensive
medications, they should be cautioned about the possi-
bility of sildenafil-induced hypotension. Because both
venous and arterial vasodilatation occur with sildenafil,
initial monitoring of the blood pressure with the insti-
tution of Viagra use would identify patients with an
undesired hypotensive blood pressure response. This is
an area of particular concern for the patient with
congestive heart failure who has a borderline low blood
volume and a low blood pressure status as well as for
the patient who is following a complicated, multidrug,
antihypertensive therapy regimen.
B. Management of Acute Ischemic Syndromes
With Patients Taking Sildenafil
1. The physician should try to establish the time of the last
dose of sildenafil. Definitive evidence is currently
lacking, but it is possible that a precipitous reduction in
blood pressure may occur over the initial 24 hours after
a dose of sildenafil. Administration of nitrates in this
time interval should be avoided. In the event that
nitrates are given after sildenafil administration, it is
essential to have the capability to support the patient
with fluid resuscitation and a-adrenergic agonists if
needed. After 24 hour, the administration of a nitrate
may be considered, but once again, appropriate caution
with careful monitoring of initial dosages must be used.
In patients in whom the half-life of sildenafil may be
prolonged, such as in renal and hepatic dysfunction or
patients concurrently taking a potent CYP 3A4 inhibi-
tor, a more extended period of time from sildenafil
administration to the time of nitrate administration may
be required. In patients with recurring mild angina after
sildenafil use, other nonnitrate antianginal agents, such
as b-blockers, should be considered.
2. Patients taking sildenafil who have an acute myocardial
infarction should be treated in the usual manner as
described in the ACC/AHA clinical practice guidelines
(32) including, where appropriate, primary angioplasty
or thrombolytics. The only difference is that nitrates are
contraindicated for these patients. If the patient had
already used nitrates and sildenafil together, the acute
myocardial infarction may have been caused by the low
diastolic perfusion pressure of the coronary circulation.
Blood pressure support may be sufficient to prevent
further myocardial damage if no acute plaque rupture is
present.
3. In patients with unstable angina, therapy should include
only nonnitrate antianginal medications but should oth-
erwise adhere to principles established in the clinical
practice guideline available from the Agency for Health
Care Policy and Research (33). To date, there is no
evidence of significant interactions between sildenafil
and heparin, b-adrenergic blockers, calcium channel
blockers, narcotics, or aspirin. These agents can be used
as appropriate. After 24 hours, nitrates may be admin-
istered if close monitoring is provided and proper
facilities are available for fluid and vasopressor support.
C. Treatment of the Hypotensive Patient With
Inadvertent Sildenafil-Nitrate Combination Effect
In patients who inadvertently received nitrates while taking
sildenafil and who manifest a severe hypotensive response,
nitrate and nitroprusside (ie, NO donor) therapy should be
immediately stopped. Depending on clinical circumstances,
any of the following therapies should be considered alone or
in combination:
1. Place the patient in Trendelenburg position.
2. Provide aggressive fluid resuscitation.
3. Provide judicious use of an intravenous a-adrenergic
agonist such as phenylephrine (Neo-Synephrine).
4. Provide an a- and b-adrenergic agonist (norepineph-
rine) for blood pressure support, with the realization
that this could exacerbate or lead to an acute ischemic
syndrome.
5. Provide intra-aortic balloon counterpulsation.
D. Limitations and Unresolved Issues
Expert Consensus Documents, as noted in the preamble, are
often written in circumstances in which the evidence base and
experience with the technology or practice are limited. This is
clearly the case with Viagra. The evidence base had signifi-
cant limitations, and many important issues remain unre-
solved. Of special significance to the current report is the fact
that the preapproval clinical trials of Viagra excluded certain
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high-risk groups of patients with significant cardiac disease
(ie, patients with heart failure, patients with myocardial
infarction or stroke within 6 months, or patients with uncon-
trolled hypertension) or patients with blood pressures of
,90/50 or .170/100 mm Hg. More research needs to be
done to assess the specific risks of Viagra use among these
cardiovascular patients.
The authors of this Expert Consensus Document identified
a number of other unresolved issues that could affect clinical
management of the cardiovascular consequences of sildenafil
use, including the following:
1. Interaction with nonaspirin antiplatelet agents (eg, ticlo-
pidine, clopidogrel, and dipyridamole).
2. Interaction with other PDE inhibitors, including specific
PDE inhibitors (eg, milrinone, vesnarinone, and enoxi-
mone) and nonspecific PDE inhibitors (eg, theophyl-
line, dipyridamole, papaverine, and pentoxifylline).
3. Central nervous system effects of sildenafil (PDE5 is
present in the brain).
4. Hypotensive effects with sildenafil alone in high-risk
cardiac patients (severe heart failure).
5. Musculoskeletal effects (myalgias with chest pains that
could be confused with angina).
As more evidence is accumulated, the ACC will consider an
update of this Expert Consensus Document.
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Illicit Substances Containing Organic Nitrates
Amyl nitrate or nitrite (It is known that amyl nitrate or nitrite is
sometimes abused. In abuse situations, amyl nitrate or nitrite may be
known by various names, including “poppers.”)
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Protease inhibitors: Crixivan (indinavir), Norvir (ritonavir), Viracept
(nelfinavir), Invirase (saquinavir)
Biaxin is a registered trademark of Abbott Laboratories. Diflucan,
Norvast and Zoloft are registered trademarks of Pfizer Inc. Sporanox,
Hismanal and Propulsid are registered trademarks of Janssen Phar-
maceutica Inc. Noroxin, Cozaar, Mevacor and Zocor are registered
trademarks of Merck & Co, Inc. Plendil and Prilosec are registered
trademarks of Astra Merck Inc. DynaCirc is a registered trademark
of Norartis Pharmaceuticals Corporation. Posicor is a registered
trademark of Roche Pharmaceuticals. Lipitor and Rezulin are regis-
tered trademarks of Parke-Davis. Baycol is a trademark of Bayer
Corporation. Prozac is a registered trademark of Eli Lilly and
Company. Luvox is a registered trademark of Solvay Pharmaceuti-
cals, Inc. Serzone is a registered trademark of Bristol-Myers Squibb
Company. Tagamet is a registered trademark of SmithKline
Beecham Pharmaceuticals. Seldane is a registered trademark of
Hoechst Marion Roussel. Viagra is a trademark of Pfizer Inc.
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